These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 15253689)

  • 41. Comparison of the efficacy of biologics versus conventional systemic therapies in the treatment of psoriasis at a comprehensive psoriasis care center.
    Au SC; Madani A; Alhaddad M; Alkofide M; Gottlieb AB
    J Drugs Dermatol; 2013 Aug; 12(8):861-6. PubMed ID: 23986158
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The two-compound formulation of calcipotriol and betamethasone dipropionate for treatment of moderately severe body and scalp psoriasis - an introduction.
    Freeman K
    Curr Med Res Opin; 2011 Jan; 27(1):197-203. PubMed ID: 21142834
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term data in the treatment of psoriasis.
    Thaçi D
    Br J Dermatol; 2008 Aug; 159 Suppl 2():18-24. PubMed ID: 18700911
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Costs of therapy with biologics in the treatment of moderate to severe plaque psoriasis in the context of the Italian health-care system.
    Terranova L; Mattozzi C; Richetta AG; Mantuano M; Cardosi L; Teruzzi C
    G Ital Dermatol Venereol; 2014 Feb; 149(1):131-43. PubMed ID: 24566574
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacoeconomic model of topical treatment options of mild to moderate psoriasis vulgaris in Germany.
    Augustin M; Radtke M; van Engen A; Ruedig C; Lapp C; Moehling U
    J Dtsch Dermatol Ges; 2009 Apr; 7(4):329-38. PubMed ID: 19243481
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The use of therapeutic interchange for biologic therapies.
    Flood J; Mihalik C; Fleming RR; Strober BE; Zucker DR; Burgoyne DS
    Manag Care; 2007 Jan; 16(1):51-62. PubMed ID: 17285813
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Consensus document on the evaluation and treatment of moderate-to-severe psoriasis. Spanish psoriasis group of the Spanish Academy of Dermatology and Venereology].
    Puig L; Bordas X; Carrascosa JM; Daudén E; Ferrándiz C; Hernanz JM; López-Estebaranz JL; Moreno JC; Sánchez-Carazo JL; Vanaclocha F; Vázquez-Veiga H;
    Actas Dermosifiliogr; 2009 May; 100(4):277-86. PubMed ID: 19463230
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The development of injectable biologic agents.
    Rich SJ
    J Manag Care Pharm; 2004 Jun; 10(3 Suppl B):S3. PubMed ID: 15320361
    [No Abstract]   [Full Text] [Related]  

  • 49. Cost-utility analysis of biologic therapies to treat chronic plaque psoriasis in Italy: the importance of using updated and adequate social tariffs to calculate quality-adjusted life-years.
    Scalone L; Cortesi PA
    BioDrugs; 2015 Feb; 29(1):69. PubMed ID: 25633571
    [No Abstract]   [Full Text] [Related]  

  • 50. Reply to Scalone and Cortesi: "Cost-utility analysis of biologic therapies to treat chronic plaque psoriasis in Italy: the importance of using updated and adequate social tariffs to calculate QALYs".
    Spandonaro F; Ayala F; Berardesca E; Chimenti S; Girolomoni G; Martini P; Peserico A; Polistena B; Guerra AP; Vena GA; Altomare G; Pinton PC
    BioDrugs; 2015 Feb; 29(1):71-2. PubMed ID: 25647521
    [No Abstract]   [Full Text] [Related]  

  • 51. The effect of psoriasis on patients' quality of life and improvements associated with alefacept therapy.
    Menter A
    J Cutan Med Surg; 2004 Dec; 8 Suppl 2():20-5. PubMed ID: 15668752
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The impact of biologics on the quality of life of psoriasis patients and the economics of psoriasis care.
    Stein KR; Pearce DJ; Feldman SR
    Semin Cutan Med Surg; 2005 Mar; 24(1):52-7. PubMed ID: 15900799
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel psoriasis therapies and patient outcomes, Part 3: Systemic medications.
    Feely MA; Smith BL; Weinberg JM
    Cutis; 2015 Jul; 96(1):47-53. PubMed ID: 26244353
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacoeconomics of Biologic Therapy.
    Bukstein DA; Luskin AT
    Immunol Allergy Clin North Am; 2017 May; 37(2):413-430. PubMed ID: 28366485
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Current status and future prospects for biologic treatments of psoriasis.
    Cline A; Hill D; Lewallen R; Feldman SR
    Expert Rev Clin Immunol; 2016 Dec; 12(12):1273-1287. PubMed ID: 27327580
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biologic therapy for psoriasis: the new therapeutic frontier.
    Singri P; West DP; Gordon KB
    Arch Dermatol; 2002 May; 138(5):657-63. PubMed ID: 12020229
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: A cross-sectional study in clinical practice.
    Carrascosa JM; Garcia-Doval I; Pérez-Zafrilla B; Carretero G; Vanaclocha F; Daudén E; De la Cueva-Dobao P; Belinchón I; Alsina M; López-Estebaranz JL; Ferrán M; Torrado R; Rivera R; Carazo C; Barboza L; Ferrándiz C;
    J Dermatolog Treat; 2015; 26(6):502-6. PubMed ID: 25886087
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recent Advances in Small Molecule and Biological Therapeutic Approaches in the Treatment of Psoriasis.
    Turbeville JG; Patel NU; Cardwell LA; Oussedik E; Feldman SR
    Clin Pharmacol Ther; 2017 Jul; 102(1):70-85. PubMed ID: 28317101
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The economic burden and quality of life of patients with psoriasis treated with biologics in China.
    Min S; Wang D; Xia J; Lin X; Jiang G
    J Dermatolog Treat; 2023 Dec; 34(1):2247106. PubMed ID: 37621166
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Biologic therapy for psoriasis: telephone triage.
    Pearce DJ; Boles A; Greist HM; Feldman SR
    Dermatol Nurs; 2005 Aug; 17(4):265-70, 295. PubMed ID: 16206681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.